September 19, 2016 02:43 PM EDT
Bioregnum
Opinion

Se­nior FDA of­fi­cials warned that ap­prov­ing $300,000 Duchenne drug will low­er agency stan­dards

In the end, Sarep­ta did many things wrong when it came to de­vel­op­ing a new drug for Duchenne mus­cu­lar dy­s­tro­phy. But it got one very …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump blog: Top HHS spokesper­son re­signs with­in weeks of be­ing sworn in

ICER finds GSK in­halers of­fer ad­van­tages over gener­ic com­peti­tors

Bio­haven’s ion chan­nel drug fails piv­otal bipo­lar ma­nia study

Pli­ant calls it quits on Phase 2b id­io­path­ic pul­monary fi­bro­sis study

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times